Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW ...

Edwards Lifesciences (NYSE:EW) saw its shares rise by 3% following news that competitor Boston Scientific (NYSE:BSX) is ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

This week, a number of companies, big and small, shared updates on their cardiovascular technology innovations at EuroPCR ...

This was the stock's fourth consecutive day of gains.

This was the stock's second consecutive day of gains.

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS).

Edwards Lifesciences EW has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

St. Luke’s Heart Team pioneers first EVOQUE tricuspid valve replacement in the region, offering new hope for patients with ...

New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms ...

Looking toward approval in the US, larger studies with careful hemodynamic data will be needed, says Martin Leon.